Phase Ib/II plans
Two Ib/II studies of ARQ-501 in combination to be initiated in Q4, 2004.
With Gemcitabine
With Taxotere
Phase Ib component to explore optimal dose schedule in combination in patients eligible for combination therapy
Phase II component in specific tumor types for formal efficacy assessment